GLYC

Uproleselan/GMI-1687

Newly-Diagnosed AML patients Fit for Chemotherapy

Stage (next event)

Expected Date

Phase 3

TBD

Catalyst Info & Data Links

MECHANISM OF ACTION

  • Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin. 

Updated by JM

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu

Lots of Uncertainty in Upcoming GLYC Sickle Cell Readout

AMP Trades Last Week

Anthera Pharmaceuticals: A Series Of Unfortunate Events

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon